奥锐特药业股份有限公司 (605116) Q2 2026 Earnings Call

Concluded Sep 8, 2026

Sep 8, 2026 0 turns

Period: FY2026 Q2
Runtime: —
Sources: 0 artifacts

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. Event details are collected in one workspace.

R&D pipeline and filings 13 2025 full-year financial results 8 Q1 2026 earnings decline 8 Domestic finished-drug channel expansion 4 API price competition 2 Capacity ramp-up / new depreciation 2

Management tone

Cautious

Net tone -15 · low hedging

Grounding quotes

“2026年第一季度公司净利润为0. 64亿元同比下降了46. 47%”
“原料药行业竞争日益激烈产品价格持续成压导致公司部分原料药产品售价有所下滑”
“公司高毛利产品与低毛利产品销售结构发生变化对整体盈利水平产生一定影响”
“随着项目陆续转雇投产公司产能尚处于逐步爬坡阶段新增折旧及运营成本对经营业绩形成一定压力”

Research coverage

0 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Company webcastOpen the original investor-relations page

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →